Insider · CIK 0001814189

Kerr Douglas

Reports to the SEC for 2 companies · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001814189

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-20	DYNDyne Therapeutics, Inc. · Stock option (right to buy)A Award	Head of R&D and CMO	AAward	+12K sh	—	—	12,000
2026-10-20	DYNDyne Therapeutics, Inc.A Award	Head of R&D and CMO	AAward	+8,000 sh	—	—	170,564
2026-09-08	DYNDyne Therapeutics, Inc.S Sale	Head of R&D and CMO	SSale	−1,290 sh	$18.88	−$24.4K	162,564
2026-09-04	DYNDyne Therapeutics, Inc.S Sale	Head of R&D and CMO	SSale	−3,745 sh	$24.35	−$91.2K	163,854
2026-08-13	DYNDyne Therapeutics, Inc.S Sale	Head of R&D and CMO	SSale	−1,556 sh	$26.28	−$40.9K	167,599
2026-06-16	DYNDyne Therapeutics, Inc.S Sale	Head of R&D and CMO	SSale	−887 sh	$18.33	−$16.3K	169,155
2026-05-13	DYNDyne Therapeutics, Inc.S Sale	Head of R&D and CMO	SSale	−1,564 sh	$18.36	−$28.7K	170,042
2026-03-05	DYNDyne Therapeutics, Inc.S Sale	Head of R&D and CMO	SSale	−904 sh	$14.90	−$13.5K	171,606
2026-02-12	DYNDyne Therapeutics, Inc.A Award	Head of R&D and CMO	AAward	+85K sh	—	—	172,510
2026-02-12	DYNDyne Therapeutics, Inc. · Stock option (right to buy)A Award	Head of R&D and CMO	AAward	+130K sh	—	—	130,000
2025-12-05	DYNDyne Therapeutics, Inc.S Sale	Head of R&D and CMO	SSale	−880 sh	$20.72	−$18.2K	87,510
2025-09-05	DYNDyne Therapeutics, Inc.S Sale	Head of R&D and CMO	SSale	−873 sh	$13.41	−$11.7K	88,390
2025-09-04	DYNDyne Therapeutics, Inc.S Sale	Head of R&D and CMO	SSale	−3,552 sh	$13.27	−$47.1K	89,263
2025-07-16	DYNDyne Therapeutics, Inc. · Stock option (right to buy)A Award	Head of R&D and CMO	AAward	+65.1K sh	—	—	65,110
2025-06-05	DYNDyne Therapeutics, Inc.S Sale	Head of R&D and CMO	SSale	−1,342 sh	$13.35	−$17.9K	92,815
2025-03-05	DYNDyne Therapeutics, Inc.S Sale	Head of R&D and CMO	SSale	−1,343 sh	$11.83	−$15.9K	94,157
2024-12-04	DYNDyne Therapeutics, Inc.A Award	Head of R&D and CMO	AAward	+48K sh	—	—	95,500
2024-12-04	DYNDyne Therapeutics, Inc. · Stock option (right to buy)A Award	Head of R&D and CMO	AAward	+76.6K sh	—	—	76,600
2024-09-03	DYNDyne Therapeutics, Inc.A Award	Head of R&D and CMO	AAward	+47.5K sh	—	—	47,500
2024-09-03	DYNDyne Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Head of R&D and CMO	AAward	+150K sh	—	—	150,300
2024-01-29	GBIOGeneration Bio Co.M Exercise/Conversion	CHIEF MEDICAL OFFICER	MExercise/Conversion	+5,021 sh	—	—	387,104
2024-01-29	GBIOGeneration Bio Co.F Tax Payment	CHIEF MEDICAL OFFICER	FTax Payment	−1,476 sh	$1.90	−$2,804.4	385,628
2024-01-29	GBIOGeneration Bio Co. · Restricted Stock UnitsM Exercise/Conversion	CHIEF MEDICAL OFFICER	MExercise/Conversion	−5,021 sh	—	—	0
2024-01-15	GBIOGeneration Bio Co.M Exercise/Conversion	CHIEF MEDICAL OFFICER	MExercise/Conversion	+7,437 sh	—	—	380,286
2024-01-15	GBIOGeneration Bio Co.F Tax Payment	CHIEF MEDICAL OFFICER	FTax Payment	−2,577 sh	$1.91	−$4,922.07	377,709
2024-01-15	GBIOGeneration Bio Co.M Exercise/Conversion	CHIEF MEDICAL OFFICER	MExercise/Conversion	+6,694 sh	—	—	384,403
2024-01-15	GBIOGeneration Bio Co.F Tax Payment	CHIEF MEDICAL OFFICER	FTax Payment	−2,320 sh	$1.91	−$4,431.2	382,083
2024-01-15	GBIOGeneration Bio Co. · Restricted Stock UnitsM Exercise/Conversion	CHIEF MEDICAL OFFICER	MExercise/Conversion	−7,437 sh	—	—	7,437
2024-01-15	GBIOGeneration Bio Co. · Restricted Stock UnitsM Exercise/Conversion	CHIEF MEDICAL OFFICER	MExercise/Conversion	−6,694 sh	—	—	20,081
2023-10-15	GBIOGeneration Bio Co.M Exercise/Conversion	CHIEF MEDICAL OFFICER	MExercise/Conversion	+7,437 sh	—	—	372,587
2023-10-15	GBIOGeneration Bio Co.F Tax Payment	CHIEF MEDICAL OFFICER	FTax Payment	−2,183 sh	$3.24	−$7,072.92	370,404
2023-10-15	GBIOGeneration Bio Co. · Restricted Stock UnitsM Exercise/Conversion	CHIEF MEDICAL OFFICER	MExercise/Conversion	−7,437 sh	—	—	7,437
2023-07-15	GBIOGeneration Bio Co.M Exercise/Conversion	CHIEF MEDICAL OFFICER	MExercise/Conversion	+7,437 sh	—	—	367,333
2023-07-15	GBIOGeneration Bio Co.F Tax Payment	CHIEF MEDICAL OFFICER	FTax Payment	−2,183 sh	$5.08	−$11.1K	365,150
2023-07-15	GBIOGeneration Bio Co. · Restricted Stock UnitsM Exercise/Conversion	CHIEF MEDICAL OFFICER	MExercise/Conversion	−7,437 sh	—	—	14,874
2023-04-15	GBIOGeneration Bio Co.M Exercise/Conversion	CHIEF MEDICAL OFFICER	MExercise/Conversion	+7,437 sh	—	—	358,963
2023-04-15	GBIOGeneration Bio Co.F Tax Payment	CHIEF MEDICAL OFFICER	FTax Payment	−2,183 sh	$4.50	−$9,823.5	356,780
2023-04-15	GBIOGeneration Bio Co. · Restricted Stock UnitsM Exercise/Conversion	CHIEF MEDICAL OFFICER	MExercise/Conversion	−7,437 sh	—	—	22,311
2023-01-20	GBIOGeneration Bio Co. · Stock Option (right to buy)A Award	CHIEF MEDICAL OFFICER	AAward	+53.6K sh	—	—	53,550
2023-01-20	GBIOGeneration Bio Co. · Restricted Stock UnitsA Award	CHIEF MEDICAL OFFICER	AAward	+26.8K sh	—	—	26,775
2023-01-15	GBIOGeneration Bio Co.M Exercise/Conversion	CHIEF MEDICAL OFFICER	MExercise/Conversion	+7,438 sh	—	—	354,104
2023-01-15	GBIOGeneration Bio Co.F Tax Payment	CHIEF MEDICAL OFFICER	FTax Payment	−2,578 sh	$5.10	−$13.1K	351,526
2023-01-15	GBIOGeneration Bio Co. · Restricted Stock UnitsM Exercise/Conversion	CHIEF MEDICAL OFFICER	MExercise/Conversion	−7,438 sh	—	—	29,748
2022-10-15	GBIOGeneration Bio Co.M Exercise/Conversion	CHIEF MEDICAL OFFICER	MExercise/Conversion	+7,438 sh	—	—	346,985
2022-10-15	GBIOGeneration Bio Co.F Tax Payment	CHIEF MEDICAL OFFICER	FTax Payment	−2,184 sh	$5.61	−$12.3K	344,801
2022-10-15	GBIOGeneration Bio Co. · Restricted Stock UnitsM Exercise/Conversion	CHIEF MEDICAL OFFICER	MExercise/Conversion	−7,438 sh	—	—	37,186
2022-07-15	GBIOGeneration Bio Co.M Exercise/Conversion	CHIEF MEDICAL OFFICER	MExercise/Conversion	+14.9K sh	—	—	343,914
2022-07-15	GBIOGeneration Bio Co.F Tax Payment	CHIEF MEDICAL OFFICER	FTax Payment	−4,367 sh	$7.18	−$31.4K	339,547
2022-07-15	GBIOGeneration Bio Co. · Restricted Stock UnitsM Exercise/Conversion	CHIEF MEDICAL OFFICER	MExercise/Conversion	−14.9K sh	—	—	44,624
2022-01-21	GBIOGeneration Bio Co. · Stock Option (right to buy)A Award	CHIEF MEDICAL OFFICER	AAward	+119K sh	—	—	119,000

Recent filings

Accepted (ET)
Oct 224
Kerr Douglas0001814189-26-000007
SEC(opens sec.gov)
Sep 84
Kerr Douglas0001814189-26-000005
SEC(opens sec.gov)
Aug 174
Kerr Douglas0001814189-26-000004
SEC(opens sec.gov)
Jun 174
Kerr Douglas0001814189-26-000002
SEC(opens sec.gov)
May 144
Kerr Douglas0001193125-26-223966
SEC(opens sec.gov)
Mar 64
Kerr Douglas0001193125-26-096517
SEC(opens sec.gov)
Feb 174
Kerr Douglas0001193125-26-055070
SEC(opens sec.gov)
Dec 54
Kerr Douglas0001193125-25-309641
SEC(opens sec.gov)
Sep 84
Kerr Douglas0000950170-25-113538
SEC(opens sec.gov)
Jul 184
Kerr Douglas0000950170-25-097006
SEC(opens sec.gov)
Jun 64
Kerr Douglas0000950170-25-083048
SEC(opens sec.gov)
Mar 74
Kerr Douglas0000950170-25-035499
SEC(opens sec.gov)
Dec 64
Kerr Douglas0000950170-24-134073
SEC(opens sec.gov)
Sep 34
Kerr Douglas0000950170-24-103037
SEC(opens sec.gov)

Companies

Address

C/O DYNE THERAPEUTICS, INC. 1560 TRAPELO ROAD

WALTHAM, MA, 02451